Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.47 USD | +1.26% | +0.58% | +17.40% |
Jun. 11 | Myriad Genetics, GSK Partner to Expand Access to HRD Diagnostic Testing | MT |
May. 31 | Qiagen, Myriad Genetics Team Up to Develop Homologous Recombination Deficiency Test | MT |
Evolution of the average Target Price on Myriad Genetics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Myriad Genetics, Inc.
Piper Sandler | |
BofA Securities | |
Goldman Sachs | |
Wells Fargo Securities | |
Wolfe Research | |
JPMorgan Chase | |
Morningstar | |
Jefferies & Co. | |
Stephens Inc. | |
Raymond James | |
SVB Securities LLC |
EPS Revisions
- Stock Market
- Equities
- MYGN Stock
- Consensus Myriad Genetics, Inc.